Sanofi's Dupixent Drug Meets Endpoints for Atopic Dermatitis Treatment

   By Marc Navarro Gonzalez

Sanofi SA (SAN.FR) said Wednesday that a phase 3 trial evaluating its drug Dupixent to treat moderate to severe atopic dermatits in adolescents met its primary and key secondary endpoints.

The French drug maker said the trial showed treatment with Dupixent as monotherapy "significantly improved measure of overall disease severity, skin clearing, itching and certain health-related quality of life measures."

Patients treated with Dupixent had significant improvement in disease severity at 16 weeks, Sanofi said.

In 2016, the U.S. Food and Drug Administration granted Breakthrough Therapy designation for Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents between 12 and 17 years old, and for the treatment of severe cases of the disease in children between six months and 11 years of age.

Write to Marc Navarro Gonzalez at marc.navarro@dowjones.com

(END) Dow Jones Newswires

May 16, 2018 01:48 ET (05:48 GMT)

Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2024 to May 2024